EXPRESSION, PURIFICATION, AND CHARACTERIZATION OF MOUSE CYP2D22
Open Access
- 1 July 2006
- journal article
- research article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 34 (7) , 1167-1174
Abstract
Metabolism of the prototype human CYP2D6 substrates debrisoquine and bufuralol proceeds at a much slower rate in mice; therefore, the mouse has been proposed as an animal model for the human CYP2D6 genetic deficiency. To interpret the molecular mechanism of this deficiency, a cDNA belonging to the CYP2D gene subfamily (Cyp2d22) has been cloned and sequenced from a mouse mammary tumor-derived cell line. In the current study, Cyp2d22 enzyme was overexpressed and purified from insect cells using a baculovirus-mediated system. The activity of this purified enzyme was directly compared with purified human CYP2D6 toward codeine, dextromethorphan, and methadone as substrates. Purified Cyp2d22 was found to catalyze the O-demethylation of dextromethorphan with significantly higher Km values (250 μM) than that (4.2 μM) exhibited by purified human CYP2D6. The Km for dextromethorphan N-demethylation by Cyp2d22 was found to be 418 μM, much lower than that observed with human CYP2D6 and near the Km for dextromethorphan N-demethylation catalyzed by CYP3A4. CYP2D6 catalyzed codeine O-demethylation, whereas Cyp2d22 and CYP3A4 mediated codeine N-demethylation. Furthermore, methadone, a known CYP3A4 substrate and CYP2D6 inhibitor, was N-demethylated by Cyp2d22 with a Km of 517 μM and Vmax of 4.9 pmol/pmol/min. Quinidine and ketoconazole, potent inhibitors to CYP2D6 and CYP3A4, respectively, did not show strong inhibition toward Cyp2d22-mediated dextromethorphan O- or N-demethylation. These results suggest that mouse Cyp2d22 has its own substrate specificity beyond CYP2D6-like-deficient activity.Keywords
This publication has 48 references indexed in Scilit:
- Metabolism of human cytochrome P450 marker substrates in mouse: a strain and gender comparisonXenobiotica, 2004
- Dopamine Formation from Tyramine by CYP2D6Biochemical and Biophysical Research Communications, 1998
- Genomic Cloning and Protein Expression of a Novel Rat Brain Cytochrome P-450 CYP2D18* Catalyzing Imipramine N-DemethylationJournal of Biological Chemistry, 1996
- P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclaturePharmacogenetics, 1996
- Involvement of Cytochrome P450 3A4 Enzyme in the N-Demethylation of Methadone in Human Liver MicrosomesChemical Research in Toxicology, 1996
- The CYP2D6B mutant allele is overrepresented in the Lewy body variant of Alzheimer's diseaseAnnals of Neurology, 1995
- Pharmacogenetic Phenotyping and GenotypingClinical Pharmacokinetics, 1994
- Metabolism and brain accumulation of tetrahydroisoquinoline (TIQ) a possible parkinsonism inducing substance, in an animal model of a poor debrisoquine metabolizerLife Sciences, 1990
- Characterization of the common genetic defect in humans deficient in debrisoquine metabolismNature, 1988
- MPTP, the neurotoxin inducing parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufI, P450db1) catalyzing debrisoquine 4-hydroxylationBiochemical and Biophysical Research Communications, 1987